A detailed history of Price T Rowe Associates Inc transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 208,499 shares of RAPT stock, worth $567,117. This represents 0.0% of its overall portfolio holdings.

Number of Shares
208,499
Previous 2,028,166 89.72%
Holding current value
$567,117
Previous $18.2 Million 96.5%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$2.89 - $9.38 $5.26 Million - $17.1 Million
-1,819,667 Reduced 89.72%
208,499 $637,000
Q1 2024

May 15, 2024

SELL
$6.87 - $26.45 $9.52 Million - $36.6 Million
-1,385,386 Reduced 40.58%
2,028,166 $18.2 Million
Q4 2023

Feb 14, 2024

SELL
$11.28 - $25.46 $1.42 Million - $3.22 Million
-126,289 Reduced 3.57%
3,413,552 $84.8 Million
Q3 2023

Nov 14, 2023

BUY
$16.34 - $24.66 $851,117 - $1.28 Million
52,088 Added 1.49%
3,539,841 $58.8 Million
Q2 2023

Aug 14, 2023

BUY
$16.06 - $21.61 $2.76 Million - $3.71 Million
171,883 Added 5.18%
3,487,753 $65.2 Million
Q1 2023

May 15, 2023

SELL
$17.19 - $30.8 $842,602 - $1.51 Million
-49,017 Reduced 1.46%
3,315,870 $60.8 Million
Q4 2022

Feb 14, 2023

BUY
$16.28 - $24.6 $4.64 Million - $7.01 Million
285,145 Added 9.26%
3,364,887 $66.6 Million
Q3 2022

Nov 14, 2022

SELL
$17.96 - $30.46 $22.5 Million - $38.2 Million
-1,254,941 Reduced 28.95%
3,079,742 $74.1 Million
Q2 2022

Aug 15, 2022

BUY
$10.26 - $23.59 $3.69 Million - $8.49 Million
359,978 Added 9.06%
4,334,683 $79.1 Million
Q1 2022

May 16, 2022

BUY
$17.02 - $40.22 $459,880 - $1.09 Million
27,020 Added 0.68%
3,974,705 $87.4 Million
Q4 2021

Feb 14, 2022

BUY
$29.5 - $39.5 $1.34 Million - $1.8 Million
45,507 Added 1.17%
3,947,685 $145 Million
Q3 2021

Nov 15, 2021

BUY
$29.86 - $39.47 $9.22 Million - $12.2 Million
308,779 Added 8.59%
3,902,178 $121 Million
Q2 2021

Aug 16, 2021

BUY
$17.99 - $40.02 $18.2 Million - $40.6 Million
1,013,553 Added 39.29%
3,593,399 $114 Million
Q1 2021

May 17, 2021

SELL
$16.0 - $24.46 $90,208 - $137,905
-5,638 Reduced 0.22%
2,579,846 $57.3 Million
Q4 2020

Feb 16, 2021

BUY
$15.89 - $40.87 $41.1 Million - $106 Million
2,585,484 New
2,585,484 $51.1 Million

Others Institutions Holding RAPT

About RAPT Therapeutics, Inc.


  • Ticker RAPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,656,600
  • Market Cap $80.7M
  • Description
  • RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...
More about RAPT
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.